🇺🇸 FDA

Intelligence · Clinical Pipeline

Arrowhead Pharmaceuticals Ireland Pipeline

All ClinicalTrials.gov programs at Arrowhead Pharmaceuticals Ireland — phase, modality, and trial IDs.

Programs
63

Quick answer

Arrowhead Pharmaceuticals Ireland has 63 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia (HTG)

    phase 3 small molecule active

    1 trial

  2. ARO-APOC3 PFS, ARO-APOC3, 0.9% Normal Saline for injection

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

  3. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia

    phase 3 small molecule active

    1 trial

  4. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  5. Calcium carbonate

    Arrowhead Pharmaceuticals Ireland Limited

    Uterine Contraction

    phase 3 small molecule completed

    1 trial

  6. Placebo of Zodasiran, ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia (HoFH)

    phase 3 small molecule active

    1 trial

  7. Plozasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia Syndrome

    phase 3 small molecule completed

    1 trial

  8. Plozasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia

    phase 3 small molecule active

    1 trial

  9. Plozasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 3 small molecule active

    1 trial

  10. Plozasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia

    phase 3 small molecule active

    2 trials

  11. Plozasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 3 small molecule active

    2 trials

  12. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  13. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  14. Statins

    Arrowhead Pharmaceuticals Ireland Limited

    Intracerebral Hemorrhage

    phase 3 small molecule active

    1 trial

  15. Tranexamic Acid

    Arrowhead Pharmaceuticals Ireland Limited

    Hemorrhagic Shock

    phase 3 small molecule completed

    1 trial

  16. Venofer 200 MG Per 10 ML Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Iron Deficiency Anemia of Pregnancy

    phase 3 small molecule active

    1 trial

  17. Zodasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  18. zodasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  19. 0.9% Sodium chloride - inhalation solution

    Arrowhead Pharmaceuticals Ireland Limited

    Inflammatory Lung Disease

    phase 2 small molecule active

    1 trial

  20. 0.9% sodium chloride - inhalation solution, ARO-MUC5AC Inhalation Solution

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma and Chronic obstructive pulmonary disease

    phase 2 small molecule active

    1 trial

  21. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  22. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  23. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  24. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  25. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  26. ARC-AAT Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha-1 Antitrypsin Deficiency

    phase 2 small molecule terminated

    2 trials

  27. ARO-AAT

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  28. ARO-ALK7

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  29. ARO-ANG 3 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  30. ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule completed

    1 trial

  31. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule active

    1 trial

  32. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Dyslipidemias

    phase 2 small molecule completed

    1 trial

  33. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule completed

    1 trial

  34. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  35. ARO-C3

    Arrowhead Pharmaceuticals Ireland Limited

    complement-mediated renal disease

    phase 2 small molecule active

    1 trial

  36. ARO-C3

    Arrowhead Pharmaceuticals Ireland Limited

    C3 Glomerulopathy

    phase 2 small molecule completed

    1 trial

  37. ARO-DIMERPA

    Arrowhead Pharmaceuticals Ireland Limited

    Hyperlipidemia; Mixed

    phase 2 small molecule active

    1 trial

  38. ARO-DM1 Intravenous (IV) Infusion

    Arrowhead Pharmaceuticals Ireland Limited

    Myotonic Dystrophy 1

    phase 2 small molecule active

    1 trial

  39. ARO-DUX4 for Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Facio-Scapulo-Humeral Dystrophy

    phase 2 small molecule active

    1 trial

  40. ARO-ENaC

    Arrowhead Pharmaceuticals Ireland Limited

    Cystic Fibrosis, Pulmonary

    phase 2 small molecule terminated

    1 trial

  41. ARO-HBV

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule completed

    1 trial

  42. ARO-HSD Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  43. ARO-INHBE

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  44. ARO-MAPT-SC

    Arrowhead Pharmaceuticals Ireland Limited

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  45. ARO-MMP7 Inhalation Solution

    Arrowhead Pharmaceuticals Ireland Limited

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  46. ARO-MUC5AC

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma

    phase 2 small molecule terminated

    1 trial

  47. ARO-RAGE

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma

    phase 2 small molecule active

    2 trials

  48. Fazisiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Arrowhead Pharmaceuticals Ireland have?

63 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.